Johnson & Johnson (JNJ) Holdings Trimmed by Page Arthur B

Page Arthur B trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 5.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,094 shares of the company’s stock after selling 2,645 shares during the period. Johnson & Johnson comprises 5.2% of Page Arthur B’s investment portfolio, making the stock its largest position. Page Arthur B’s holdings in Johnson & Johnson were worth $5,966,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in JNJ. Lenox Wealth Advisors Inc. lifted its position in shares of Johnson & Johnson by 0.7% during the first quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock worth $108,000 after purchasing an additional 6 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. lifted its position in shares of Johnson & Johnson by 241.0% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock worth $149,000 after purchasing an additional 841 shares in the last quarter. Ullmann Financial Group Inc. acquired a new position in shares of Johnson & Johnson during the first quarter worth $186,000. Taylor Wealth Management Partners lifted its position in shares of Johnson & Johnson by 19.8% during the first quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock worth $188,000 after purchasing an additional 250 shares in the last quarter. Finally, Foundation Resource Management Inc. acquired a new position in shares of Johnson & Johnson during the first quarter worth $204,000. 66.00% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This story was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://ledgergazette.com/2017/09/16/johnson-johnson-jnj-holdings-trimmed-by-page-arthur-b.html.

A number of research analysts have recently commented on JNJ shares. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 5th. Cowen and Company set a $147.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Thursday, August 24th. UBS AG reissued a “buy” rating and set a $148.00 target price on shares of Johnson & Johnson in a research report on Thursday, August 31st. BidaskClub cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 1st. Finally, Jefferies Group LLC reissued a “hold” rating and set a $140.00 target price on shares of Johnson & Johnson in a research report on Friday, June 16th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $134.60.

Johnson & Johnson (NYSE JNJ) traded up 0.20% during mid-day trading on Friday, reaching $134.45. 15,522,011 shares of the company’s stock traded hands. The stock has a market capitalization of $360.86 billion, a PE ratio of 22.75 and a beta of 0.79. The firm’s 50-day moving average price is $132.62 and its 200 day moving average price is $129.18. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $137.08.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, topping the consensus estimate of $1.79 by $0.04. The firm had revenue of $18.84 billion during the quarter, compared to analysts’ expectations of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. Johnson & Johnson’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period last year, the business earned $1.74 earnings per share. Equities research analysts predict that Johnson & Johnson will post $7.18 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th were given a $0.84 dividend. The ex-dividend date of this dividend was Friday, August 25th. This represents a $3.36 annualized dividend and a yield of 2.50%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 56.76%.

In related news, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the transaction, the vice president now directly owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction on Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the transaction, the vice president now directly owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply